Serum 25-hydroxyvitamin D concentrations and risk for hip fractures. by Cauley, Jane A et al.
UC Davis
UC Davis Previously Published Works
Title
Serum 25-hydroxyvitamin D concentrations and risk for hip fractures.
Permalink
https://escholarship.org/uc/item/3hg5155b
Journal
Annals of internal medicine, 149(4)
ISSN
0003-4819
Authors
Cauley, Jane A
Lacroix, Andrea Z
Wu, LieLing
et al.
Publication Date
2008-08-01
DOI
10.7326/0003-4819-149-4-200808190-00005
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Serum 25-Hydroxyvitamin D Concentrations and Risk for Hip Fractures
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Jennifer S. Lee, MD; Rebecca D. Jackson, MD; John A. Robbins, MD; Chunyuan Wu, MS; Frank Z. Stanczyk, PhD; Meryl S. LeBoff, MD;
Jean Wactawski-Wende, PhD; Gloria Sarto, MD; Judith Ockene, PhD; and Steven R. Cummings, MD
Background: The relationship between serum 25-hydroxyvitamin D
[25(OH) vitamin D] concentration and hip fractures is unclear.
Objective: To see whether low serum 25(OH) vitamin D concen-
trations are associated with hip fractures in community-dwelling
women.
Design: Nested case–control study.
Setting: 40 clinical centers in the United States.
Participants: 400 case-patients with incident hip fracture and 400
control participants matched on the basis of age, race or ethnicity,
and date of blood draw. Both groups were selected from 39 795
postmenopausal women who were not using estrogens or other
bone-active therapies and who had not had a previous hip fracture.
Measurements: Serum 25(OH) vitamin D was measured and pa-
tients were followed for a median of 7.1 years (range, 0.7 to 9.3
years) to assess fractures.
Results: Mean serum 25(OH) vitamin D concentrations were lower
in case-patients than in control participants (55.95 nmol/L [SD,
20.28] vs. 59.60 nmol/L [SD, 18.05]; P 0.007), and lower serum
25(OH) vitamin D concentrations increased hip fracture risk (ad-
justed odds ratio for each 25-nmol/L decrease, 1.33 [95% CI, 1.06
to 1.68]). Women with the lowest 25(OH) vitamin D concentra-
tions (47.5 nmol/L) had a higher fracture risk than did those with
the highest concentrations (70.7 nmol/L) (adjusted odds ratio,
1.71 [CI, 1.05 to 2.79]), and the risk increased statistically signifi-
cantly across quartiles of serum 25(OH) vitamin D concentration (P
for trend 0.016). This association was independent of number of
falls, physical function, frailty, renal function, and sex-steroid hor-
mone levels and seemed to be partially mediated by bone resorp-
tion.
Limitations: Few case-patients were nonwhite women. Bone min-
eral density and parathyroid hormone levels were not accounted for
in the analysis.
Conclusion: Low serum 25(OH) vitamin D concentrations are as-
sociated with a higher risk for hip fracture.
Ann Intern Med. 2008;149:242-250. www.annals.org
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Vitamin D deficiency is common in older adults, espe-cially during the winter (1) and in homebound popu-
lations (2), general medical inpatients (3), and community-
dwelling women admitted to the hospital with acute hip
fracture (4). A recently published evidence-based report on
vitamin D and bone health (5) found the level of evidence
for an association between serum 25-hydroxyvitamin D
[25(OH) vitamin D] concentrations and fracture risk to be
inconsistent (5). Since publication of that review, 1 pro-
spective study (6) reported no relationship between serum
25(OH) vitamin D concentrations and fractures, whereas
another (7) reported a significantly lower risk for hip frac-
ture with 25(OH) vitamin D concentrations greater than
60 nmol/L.
Vitamin D concentration could be associated with
fractures in several ways. It could influence muscle strength
and balance, both of which contribute to falls and disabil-
ity (8–10). The association between 25(OH) vitamin D
concentrations and fracture may also be influenced by re-
nal function, because renal insufficiency has been linked to
fracture (11) and to vitamin D deficiency (12). Several
interactions between vitamin D and estrogen receptors
have been described (13); hormone therapy has been
shown to reverse abnormalities in vitamin D metabolism
(14), and low vitamin D concentrations have also been
linked to higher bone turnover (15, 16). Thus, sex-steroid
hormones and bone turnover could contribute to the asso-
ciation between 25(OH) vitamin D concentration and
fractures.
We conducted a nested case–control study within the
WHI-OS (Women’s Health Initiative Observational
Study) among 400 case-patients with adjudicated incident
hip fracture and 400 control participants. We tested
whether low serum 25(OH) vitamin D concentrations are
associated with a higher risk for hip fractures in commu-
nity-dwelling women and whether this relationship may be
mediated by poor physical functioning, frailty, falls, sex-
steroid hormones, renal function, or bone turnover.
METHODS
Study Population
Our study population came from the WHI-OS, a pro-
spective cohort study that enrolled 93 676 women between
1994 and 1998 at 40 U.S. clinical centers (age range, 50 to
79 years). Study methods are described in detail elsewhere
(17). In brief, women were eligible if they were postmeno-
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pausal, were unlikely to move or die within 3 years, were
not enrolled in the WHI clinical trials, and were not cur-
rently participating in any other clinical trial. The human
subjects review committees from each participating institu-
tion approved the study.
Follow-up and Outcome Ascertainment
We sent women questionnaires annually to report any
hospitalization and other outcomes, including fractures. As
of August 2004, median follow-up duration was 7.1 years
(range, 0.7 to 9.3 years). At that time, 3.7% of participants
had withdrawn or were lost to follow-up and 5.3% had
died. We reviewed medical records to verify cases of hip
fracture, and blinded central adjudicators confirmed the
cases (18). We excluded patients with pathologic hip frac-
tures.
Nested Case–Control Study Design
The present study is a case–control study nested
within the prospective design of WHI-OS. We excluded
women who had a history of hip fracture; were receiving
hormone therapy up to 1 year before enrollment; or were
currently receiving androgens, selective estrogen receptor
modulators, antiestrogens, or other osteoporosis treatments
(bisphosphonates, calcitonin, or parathyroid hormone).
We also excluded women with insufficient serum stored or
of unknown ethnicity, leaving 39 793 eligible participants.
Of these, 404 women had a hip fracture. We randomly
selected 400 of these women to form the incident hip frac-
ture group. For each case-patient, we selected 1 control
participant who was within 1 year of the case-patient’s age
at screening, was of matching race or ethnicity, and had
their blood drawn within 120 days of the case-patient’s
blood draw date; 99% of case-patients and control partic-
ipants were matched within 30 days.
Baseline Clinical Variables
We divided clinical centers into 3 geographic regions
on the basis of latitude: northern (40 °N), middle (35 to
40 °N), and southern (35 °N). We ascertained all covari-
ates at baseline. Clinic interviewers recorded current use of
prescription medications by direct inspection of medicine
containers. We entered prescription names into the WHI
database and assigned drug codes by using Medispan soft-
ware (First DataBank, San Bruno, California). Average
amounts of elemental calcium and vitamin D preparations
were entered directly from supplement containers. Dietary
intakes of calcium and vitamin D were assessed by using a
semiquantitative food-frequency questionnaire (19). Total
calcium and vitamin D intake was defined as the sum of
diet and supplements.
We used questionnaires to ascertain date of birth, race
or ethnicity, age at menopause, history of any fracture after
age 55 years, smoking, parental history of hip fracture,
self-rated health status, and alcohol consumption. We
classfied physical activity on the basis of frequency and
duration of walking and mild, moderate, and strenuous
activities in the previous week. We calculated kilocalories
of energy expended in 1 week as the metabolic equivalent
(kcal hours/week per kg) (20). We measured physical func-
tion by using the RAND Short Form-36 physical function
scale, which comprises 10 items measuring whether health
now limits physical function in moderate or vigorous ac-
tivity (2 items); strength to lift, carry, stoop, bend, or stair
climb (4 items); ability to walk various distances without
difficulty (3 items); and self-care (1 item) (21). The scale is
scored from 0 to 100, with higher scores indicating better
physical function. We compared women with a score
greater than 90 versus those with a score less than or equal
to 90, a cutoff value corresponding to the median score.
We computed a frailty score, which included self-reported
muscle weakness and impaired walking speed (RAND
Short Form-36 physical function scale score 75), exhaus-
tion (RAND Short Form-36 vitality scale score 55), low
physical activity (lowest quartile of physical activity), and
unintended weight loss between baseline and 3 years of
follow-up (22). A woman was considered frail if she re-
ported 3 or more of these indicators. Weight was measured
on a balance-beam scale with the participant dressed in
indoor clothing without shoes. Height was measured by
using a wall-mounted stadiometer. Body mass index was
calculated as weight (in kg) divided by height (in m2).
Laboratory Procedures
Laboratory personnel blinded to case–control status
obtained a 12-hour fasting blood sample at the baseline
visit, which was processed and stored at 80 °C according
to strict quality control procedures (23). Serum 25(OH)
vitamin D concentrations and sex-steroid hormone levels
were measured at the Reproductive Endocrine Research
Context
Vitamin D supplementation may help prevent fractures,
but the relationship between blood vitamin D concentra-
tions and fracture risk is unclear.
Contribution
These authors observed an increased risk for hip fracture
among women with lower serum 25-hydroxyvitamin D
[25(OH) vitamin D] concentrations that was independent
of measures of frailty, body mass index, physical function,
and falls.
Caution
The authors did not measure bone mineral density (BMD),
so they could not determine whether 25(OH) vitamin D
concentrations give different information about fracture
risk than that offered by BMD.
Implication
Low serum 25(OH) vitamin D concentrations seem to be
associated with a higher hip fracture risk.
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Laboratory at the University of Southern California. 25-
Hydroxyvitamin vitamin D was measured by using a ra-
dioimmunoassay with DiaSorin reagents (DiaSorin, Still-
water, Minnesota). The sensitivity of the assay was 3.75
nmol/L. The interassay coefficients of variation were
11.7%, 10.5%, 8.6%, and 12.5% at 14.0, 56.8, 82.5, and
122.5 nmol/L, respectively.
Estradiol and testosterone concentrations were quanti-
fied by using sensitive and specific radioimmunoassays after
organic solvent extraction and celite column partition
chromatography (24–27). The intra- and interassay coeffi-
cients of variation were 7.9% and 8% to 12%, respectively,
for estradiol and 6% and 10% to 12%, respectively, for
testosterone. We calculated bioavailable hormone concen-
trations by using mass action equations (28–30). We mea-
sured sex hormone–binding globulin by using a solid-
phase, 2-site chemiluminescent immunoassay. The intra-
and interassay coefficients of variation were 4.1% to 7.7%
and 5.8% to 13%, respectively. Serum cystatin C, a marker
of renal function that is independent of age and weight,
was measured at Medical Research Laboratories Interna-
tional, Highland Heights, Kentucky, by using the Dade
Behring BN-II nephelometer and Dade Behring reagents
(Dade Behring, Ramsey, Minnesota) in a particle-enhanced
immunonepholometric assay. Serum C-terminal telopep-
tide of type I collagen and aminoterminal procollagen ex-
tensions propeptide were measured by immunoassay (Synarc,
Lyon, France).
Statistical Analysis
We used chi-square and t tests to compare baseline
characteristics between case-patients with hip fracture and
matched control participants. We assigned 25(OH) vita-
min D concentrations to quartile categories defined on the
basis of the distribution in the control participants. To
further assess confounding, we compared baseline charac-
teristics across quartiles of 25(OH) vitamin D concentra-
tions in case-patients and control participants combined.
We calculated the P values for trend by using logistic re-
gression and coding the variable of interest as a continuous
variable. We assessed the association between serum
25(OH) vitamin D concentrations and incident hip frac-
ture in conditional logistic regression models that retained
the matched case–control design. We first examined the
unadjusted associations and then adjusted for age, body
mass index, parental history of hip fracture, previous frac-
tures, smoking, alcohol use, total calcium intake, oral cor-
ticosteroid use, and geographic location. We had infor-
mation on 25(OH) vitamin D concentrations in 799
individuals.
We calculated odds ratios and 95% CIs from the con-
ditional logistic regression models for every 2.5-nmol/L
and 25-nmol/L decrease in 25(OH) vitamin D concentra-
tions and across quartiles. We defined the highest quartile
of 25(OH) vitamin D concentration as the reference
group. We separately examined the association in women
younger than age 70 years and women 70 years of age or
older, as well as the interaction of age and 25(OH) vitamin
D concentrations. We used nonparametric smoothing
techniques to test whether the relationship was linear or a
threshold one, at a prespecified threshold of 50 nmol/L.
To investigate mechanisms by which 25(OH) vitamin
D concentration might be associated with hip fracture, we
added the following variables one at a time to the base
model to determine their effect on the association between
serum 25(OH) vitamin D concentration and hip fracture:
markers for deteriorating health status (poor physical func-
tion, frailty score [22], number of falls, sex-steroid hor-
mones, renal function (cystatin C), and bone turnover (se-
rum C-terminal telopeptide of type I collagen and
aminoterminal procollagen extensions propeptide). We
then adjusted for all the variables simultaneously (except
for frailty, which we hypothesized would be correlated with
measures of physical function because both rely on the
RAND Short Form-36 physical function scale). We hy-
pothesized that the association between 25(OH) vitamin D
concentration and hip fracture would be reduced after ad-
justment for these factors if they are in the causal pathway.
The Hosmer–Lemeshow goodness-of-fit test was used to
evaluate the models (31). All models indicated excellent fit
for the data, and the area under the curve for our summary
multivariate model was 0.69.
Our study had 90% power (with a 2-sided  level of
0.05) to detect a 0.14-SD difference in 25(OH) vitamin D
concentrations and a relative risk for fracture of 1.6 be-
tween case-patients and control participants.
Role of the Funding Source
The WHI program is funded by the National Heart,
Lung and Blood Institute, National Institutes of Health,
U.S. Department of Health and Human Services. The
sponsor played a role in the design and analysis of the
WHI.
RESULTS
Participant Characteristics
The average age of the case-patients was 71 years (SD,
6.15); one third was older than 70 years of age and 95%
were white (Table 1). Compared with control participants,
case-patients had a lower body mass index; performed less
physical activity; were more likely to report oral corticoste-
roid use, fair or poor health status, poor physical function,
and smoking; and were more likely to be considered frail.
Mean 25(OH) vitamin D concentrations were lower in
case-patients than in control participants (mean, 55.95
nmol/L [SD, 20.28] vs. 59.60 nmol/L [SD, 18.05]; P 
0.007). Case-patients had a lower calcium intake and lower
sex-steroid hormone levels but higher cystatin C and bone
resorption marker levels than did control participants.
Hormone therapy use, alcohol intake, use of vitamin D
supplements or dietary vitamin D, personal or family his-
tory of fracture, geographic location, and bone formation
Article Vitamin D Concentrations and Risk for Hip Fractures
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Table 1. Baseline Characteristics
Characteristic Control
Participants
Case-Patients P Value 25(OH) Vitamin D Level P Value
First Quartile
(9.2–47.5
nmol/L)
Second Quartile
(47.6–60.1
nmol/L)
Third Quartile
(60.2–70.6
nmol/L)
Fourth Quartile
(70.7–121.5
nmol/L)
Age 70 y, n (%) 132 (33.0) 132 (33.0) 1.00 84 (34.43) 57 (29.23) 54 (32.34) 68 (35.23) 0.58
White, n (%) 380 (95.0) 380 (95.0) 1.00 224 (91.80) 184 (94.36) 163 (97.60) 188 (97.41) 0.017
Body mass index,
n (%)
27.41 (5.13) 26.04 (5.15) 0.001 27.70 (5.72) 27.04 (4.76) 26.14 (4.87) 25.75 (25.75) 0.001
25 kg/m2 144 (36.09) 193 (48.61) 0.001 91 (37.45) 70 (36.27) 77 (46.11) 98 (51.04) 0.002
25 to 30 kg/m2 150 (37.59) 127 (31.99) 80 (32.92) 72 (37.31) 63 (37.72) 62 (32.29)
30 kg/m2 105 (26.32) 77 (19.40) 72 (29.63) 51 (26.42) 27 (16.17) 32 (16.67)
Previously received
hormone
therapy, n (%)
98 (24.50) 95 (23.75) 0.80 57 (23.36) 44 (22.56) 48 (28.74) 43 (22.28) 0.45
Oral corticosteroid
use, n (%)
3 (0.75) 14 (3.50) 0.007 7 (2.87) 3 (1.54) 1 (0.60) 6 (3.11) 0.29
RAND
SF-36
physical
function
scale score
90, n (%)
117 (29.77) 86 (21.66) 0.009 47 (19.50) 56 (29.02) 38 (23.17) 61 (31.94) 0.015
Mean total physical
activity (SD),
MET-h/wk
13.86 (15.32) 10.71 (12.67) 0.002 10.31 (15.09) 10.69 (10.37) 12.88 (12.08) 15.92 (17.0) 0.001
Frailty, n (%)* 66 (16.50) 89 (22.25) 0.040 65 (26.64) 29 (14.87) 31 (18.56) 30 (15.54) 0.005
Fair/poor
self-reported
health status,
n (%)
42 (10.69) 61 (15.37) 0.051 44 (18.26) 24 (12.44) 17 (10.30) 18 (9.47) 0.029
Smoking, n (%)
Past smoker 171 (43.18) 144 (36.55) 0.001 92 (37.86) 70 (36.65) 72 (43.90) 81 (42.41) 0.124
Current smoker 10 (2.53) 36 (9.14) 22 (9.05) 10 (5.24) 5 (3.05) 8 (4.19)
Mean alcohol
intake (SD),
drinks/wk
3.40 (1.67) 3.37 (1.60) 0.839 3.29 (1.62) 3.39 (1.67) 3.35 (1.63) 3.51 (1.60) 0.58
Mean 25(OH)
vitamin D
level (SD),
nmol/L
59.60 (18.05) 55.95 (20.28) 0.007 35.83 (8.33) 53.95 (3.73) 65.13 (3.05) 83.00 (10.80) 0.001
Quartile median – – – 37.1 54.0 65.1 80.4 –
Received vitamin D
supplement,
n (%)
189 (47.25) 195 (48.75) 0.67 63 (25.82) 96 (49.23) 102 (61.08) 123 (63.73) 0.001
Mean total vitamin
D intake (SD),
IU/d
373 (275) 383 (396) 0.707 262 (332) 361 (263) 439 (403) 480 (307) 0.001
Mean total calcium
intake (SD),
mg/d
1167.01 (683.85) 1072.47 (694.23) 0.053 906.38 (567.86) 1087.03 (702.50) 1215.80 (731.58) 1341.99 (703.77) 0.001
History of fracture
at or after age
55 y, n (%)
82 (20.50) 96 (24.00) 0.23 49 (20.08) 35 (17.95) 39 (23.35) 55 (28.50) 0.065
Parents had hip
fracture, n (%)
64 (16.00) 80 (20.00) 0.141 48 (19.67) 30 (15.38) 28 (16.77) 37 (19.17 0.63
Geographic region,
n (%)
Southern (35 °N) 108 (27.00) 106 (26.50) 0.24 56 (22.95) 48 (24.62) 48 (28.74) 62 (32.12) 0.011
Middle (35–40 °N) 95 (23.75) 115 (28.75) 59 (24.18) 64 (32.82) 32 (19.16) 54 (27.98)
Northern (40 °N) 197 (49.25) 179 (44.75) 129 (52.87) 83 (42.56) 87 (52.10) 77 (39.90)
Mean bioavailable
estradiol level
(SD), pg/mL
7.54 (4.54) 6.57 (4.34) 0.002 7.79 (4.82) 7.01 (4.68) 6.50 (4.0) 6.64 (4.05) 0.013
Mean bioavailable
testosterone
level (SD), pg/mL
12.59 (6.98) 10.90 (6.26) 0.001 12.43 (7.21) 11.27 (5.68) 11.43 (6.50) 11.66 (7.04) 0.27
Mean cystatin C
level (SD),
mg/L
1.06 (0.24) 1.10 (0.30) 0.023 1.12 (0.37) 1.06 (0.21) 1.07 (0.23) 1.04 (0.20) 0.017
Continued on following page
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did not differ between case-patients and control partici-
pants.
Comparisons across Quartiles of 25(OH) Vitamin D
The percentage of nonwhite, obese, and frail women
decreased with increasing 25(OH) vitamin D concentra-
tions, as did the percentage of those with fair or poor
health status (Table 1). Physical function and physical ac-
tivity increased with increasing concentration. Use of vita-
min D supplements, vitamin D intake, and calcium intake
also increased across quartiles of 25(OH) vitamin D con-
centration. A lower percentage of participants from the
northern region were in the highest vitamin D quartile.
Sex-steroid, cystatin C, and bone resorption marker levels
all decreased with increasing vitamin D concentrations.
25(OH) Vitamin D Concentration and Hip Fracture
Serum 25 (OH) vitamin D concentrations were asso-
ciated with hip fracture (unadjusted odds ratio for incident
hip fracture per 25-nmol/L decrease in concentration, 1.30
[95% CI, 1.07 to 1.58]) (Table 2). Further multivariate
adjustment had little effect on the risk estimate. The in-
creased risk for hip fracture was primarily confined to
women with the lowest 25(OH) vitamin D concentrations
(multivariate-adjusted odds ratio of hip fracture for women
in quartile 1 compared with women in quartile 4, 1.71
[CI, 1.05 to 2.79]) (Table 3).
A model testing the specific 25(OH) vitamin D
threshold of less than 50 nmol/L did not differ significantly
from the linear model (P  0.78), suggesting a continuous
linear relationship between serum 25(OH) vitamin D con-
centration and hip fracture, at least within the ranges of
25(OH) vitamin D concentrations in our study. The rela-
tionship between 25(OH) vitamin D concentration and
hip fracture did not differ by age (P for interaction
0.62).
Potential Mediators
The average number of falls during follow-up did not
differ between case-patients (mean, 2.36 [SD, 2.75]) and
control participants (mean, 2.82 [SD, 3.5]) (P  0.09) or
across 25(OH) vitamin D concentration quartiles. Adjust-
ment for frailty, physical functioning, and falls resulted in
similar small attenuations in the association between
25(OH) vitamin D concentration and hip fractures (Table
3). Adjustment for sex-steroid hormones also attenuated
the risk estimate, but less so than adjustment for frailty,
physical functioning, and falls. Adjustment for serum C-
terminal telopeptide of type I collagen individually and for
Table 1—Continued
Characteristic Control
Participants
Case-Patients P Value 25(OH) Vitamin D Level P Value
First Quartile
(9.2–47.5
nmol/L)
Second Quartile
(47.6–60.1
nmol/L)
Third Quartile
(60.2–70.6
nmol/L)
Fourth Quartile
(70.7–121.5
nmol/L)
Mean PINP level
(SD), ng/mL
49.64 (23.71) 51.00 (23.03) 0.42 49.04 (21.44) 51.65 (21.41) 51.68 (51.68) 49.34 (27.89) 0.53
Mean CTx level
(SD), ng/mL
0.41 (0.19) 0.45 (0.21) 0.016 0.45 (0.22) 0.44 (0.19) 0.43 (0.21) 0.39 (0.16) 0.022
25(OH) vitamin D 25-hydroxyvitamin D; CTx serum C-terminal telopeptide of type I collagen; MET metabolic equivalent; PINP amino proterminal procollagen
extension propeptide; SF-36  Short Form-36.
* Frailty was defined as 3 of the following: muscle weakness, slow walking speed, exhaustion, low physical activity, and unintentional weight loss (22).
Table 2. Odds Ratios of Risk for Hip Fracture*
25-Hydroxyvitamin D Level Unadjusted Odds Ratio
(95% CI)
Adjusted Odds Ratio
(95% CI)†
Per 2.5-nmol/L decrease‡ 1.03 (1.01–1.05) 1.03 (1.01–1.05)
Per 25-nmol/L decrease 1.30 (1.07–1.58) 1.33 (1.06–1.68)
Quartile (according to control group)
First (9.2–47.5 nmol/L) 1.73 (1.13–2.66) 1.71 (1.05–2.79)
Second (47.6–60.1 nmol/L) 1.08 (0.72–1.63) 1.09 (0.70–1.71)
Third (60.2–70.6 nmol/L) 0.78 (0.50–1.20) 0.82 (0.51–1.31)
Fourth (70.7–121.5 nmol/L) 1.00 (reference) 1.00 (reference)
* We selected and matched case-patients with control participants according to age, race or ethnicity, and blood draw date. Eighteen case–control pairs were missing from
our multivariate models because of missing values. We excluded these pairs from our unadjusted models, even when values were not missing, to provide similar risk estimates
from the same analytic samples.
† Multivariate adjustment includes age, body mass index, parental history of hip fracture, history of fracture, smoking, alcohol use, total calcium intake, oral corticosteroid
use, and geographic region.
‡ P value for linear trend  0.009 for unadjusted and 0.015 for multivariate-adjusted models; models based on a 25-hydroxyvitamin D threshold level of 50 nmol/L fit no
better than the linear models.
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all variables simultaneously resulted in the greatest attenu-
ations in odds ratios and seemed to eliminate the associa-
tion between 25(OH) vitamin D concentration and hip
fracture in women in the lowest 25(OH) vitamin D con-
centration quartile. However, the overall trend of the rela-
tionship between 25(OH) vitamin D concentration and
hip fracture across quartiles remained statistically signifi-
cant (fully adjusted odds of fracture for women with the
lowest concentrations [quartile 1], 1.72 [CI, 0.98 to 3.02];
P  0.060; P for trend 0.029).
DISCUSSION
In our prospective, nested case–control study, we
found that women with the lowest 25(OH) vitamin D
concentrations (47.6 nmol/L) at study entry had a sig-
nificantly greater increased risk for subsequent hip fracture
during the next 7 years than did women with the highest
concentrations (70.7 nmol/L). The association between
25(OH) vitamin D concentration and hip fracture was
linear and did not seem to differ by age.
By using an English-language MEDLINE search through
January 2008, we identified 5 prospective studies of serum
vitamin D concentrations and fracture. Our results are consis-
tent with a recent report from the NHANES III (Third Na-
tional Health and Nutrition Examination Survey) (7), in
which the relative risk for hip fracture among participants
with 25(OH) vitamin D concentrations greater than 60
nmol/L compared with those who had lower concentra-
tions was 0.64 (CI, 0.46 to 0.89). Similarly, in a cohort
study of Swedish women, those with serum 25(OH) vita-
min D concentrations less than 52.5 nmol/L had a 2-fold
increased risk for fracture (32). Two previous cohort stud-
ies (33, 34) failed to find a significant association between
25(OH) vitamin D concentration and fracture; however,
these were limited by small sample size and high lost-to-
follow-up rates (33) or use of an older assay (34). A nested
case–control study of 730 case-patients and 1445 control
participants with incident fracture found no evidence of an
association between 25(OH) vitamin D concentration and
fracture (6). However, the investigators studied a heteroge-
neous group of fractures, including only 22 hip fractures,
and studied a younger population (mean age, 53 years).
Vitamin D concentration may be more strongly linked to
frailty-related fractures, such as hip fractures, which tend to
occur in much older women.
Table 3. Adjusted Odds Ratios of Risk for Hip Fracture, by Vitamin D Quartile
Analysis Odds Ratio (95% CI) P Value
for Linear
TrendFirst Quartile
(9.2–47.5
nmol/L)
(n  244)
Second Quartile
(47.6–60.1
nmol/L)
(n  195)
Third Quartile
(60.2–70.6
nmol/L)
(n  167)
Fourth Quartile
(70.7–121.5
nmol/L)
(n  193)
Base analysis* 1.71 (1.05–2.79) 1.09 (0.70–1.71) 0.82 (0.51–1.31) 1.00 (reference) 0.016
P value 0.032 0.76 0.45 – –
Adjusted analysis
Frailty score† 1.65 (1.01–2.69) 1.08 (0.68–1.70) 0.81 (0.50–1.30) 1.00 (reference) 0.022
P value 0.047 0.74 0.38 – –
RAND SF-36 physical functioning scale score 90 1.68 (1.02–2.76) 1.15 (0.73–1.83) 0.81 (0.50–1.31) 1.00 (reference) 0.016
P value 0.041 0.55 0.39 – –
Total number of falls during follow-up 1.66 (1.00–2.77) 1.14 (0.70–1.85) 0.86 (0.52–1.42) 1.00 (reference) 0.018
P value 0.039 0.59 0.55 – –
Bioavailable estradiol 1.75 (1.06–2.87) 1.01 (0.64–1.59) 0.75 (0.46–1.23) 1.00 (reference) 0.022
P value 0.028 0.98 0.25 – –
Bioavailable testosterone 1.72 (1.05–2.83) 1.05 (0.67–1.66) 0.82 (0.50–1.34) 1.00 (reference) 0.021
P value 0.031 0.83 0.42 – –
Cystatin C 1.68 (1.02–2.76) 1.18 (0.70–1.76) 0.81 (0.50–1.31) 1.00 (reference) 0.019
P value 0.042 0.66 0.39 – –
PINP 1.69 (1.04–2.77) 1.05 (0.67–1.67) 0.84 (0.52–1.35) 1.00 (reference) 0.022
P value 0.036 0.82 0.47 – –
CTx 1.58 (0.97–2.60) 1.03 (0.66–1.64) 0.83 (0.51–1.34) 1.00 (reference) 0.040
P value 0.069 0.89 0.44 – –
Summary multivariate model‡ 1.72 (0.98–3.02) 1.21 (0.71–2.05) 0.84 (0.48–1.46) 1.00 (reference) 0.029
P value 0.060 0.48 0.53 – –
CTx  serum C-terminal telopeptide of type I collagen; PINP  amino proterminal procollagen extension propeptide; SF-36  Short Form-36.
* Matched on age, race or ethnicity, and blood draw date and controlled for age, body mass index, parental history of hip fracture, history of fracture, smoking, alcohol use,
total calcium intake (from diet, supplements, and medications, per 100-mg increase), oral corticosteroid use, and geographic region.
† Frailty was defined as 3 of the following: muscle weakness, slow walking speed, exhaustion, low physical activity, and unintentional weight loss (23).
‡ Matched on age, race or ethnicity, and blood draw date and controlled for age; body mass index; parental history of hip fracture; history of fracture; smoking; alcohol use;
total calcium intake (from diet, supplement and medications, per 100-mg increase); oral corticosteroid use; geographic region; frailty; total number of falls; and levels of
bioavailable estradiol, bioavailable testosterone, cystatin C, PINP, and CTx.
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The mechanism for the association is unclear. C-ter-
minal telopeptide of type I collagen, a marker of bone
resorption, tended to be higher among case-patients with
the lowest 25(OH) vitamin D concentrations, an associa-
tion that may be driven by higher parathyroid hormone
levels in this group (2). Adjustment for C-terminal telopep-
tide of type I collagen resulted in the largest attenuation of
risk in women with the lowest 25(OH) vitamin D concen-
trations (unadjusted odds ratio, 1.71 [CI, 1.05 to 2.79];
C-terminal telopeptide of type I collagen–adjusted odds
ratio, 1.58 [CI, 0.97 to 2.60]), suggesting that high bone
resorption is an important mechanism for the association.
The increased fracture risk could also be related to
impaired muscle strength and balance and poor physical
function, all of which could lead to an increased risk for
falls (8–10). Case-patients with hip fractures had lower
physical function scores and were more likely to be frail,
whereas higher 25(OH) vitamin D concentrations were
associated with a lower likelihood of being frail and with
higher physical function. Adjustment for physical function,
frailty, and falls attenuated slightly the apparent association
between 25(OH) vitamin D concentrations and hip frac-
ture; however, the association remained even after we ad-
justed for these factors. The association also remained after
we adjusted for sex-steroid hormone level and measures of
renal function.
Finally, we adjusted for geographic location in all our
analyses, given the association between vitamin D defi-
ciency and northern latitude (35). Women from northern
regions (40 °N) had lower 25(OH) vitamin D concen-
trations; however, the relationship between 25(OH) vita-
min D concentrations and hip fracture was independent of
geographic location. Also, obesity was statistically signifi-
cantly less prevalent in the participants with the highest
25(OH) vitamin D concentrations, consistent with the
lower bioavailability of vitamin D reported in obese pa-
tients (36) and with reports of an inverse association be-
tween 25(OH) vitamin D concentrations and adiposity
(37, 38). Lower 25(OH) vitamin D concentrations in
obese patients may reflect lower physical activity (less sun-
light exposure) and deposition in body fat compartments
(36). However, the association between 25(OH) vitamin
D concentration and hip fracture was independent of obe-
sity.
The optimal serum 25(OH) vitamin D concentration
needed to maintain bone health has not been established.
Optimal concentration has been defined as that at which
serum parathyroid hormone levels plateau in the normal
range (39); however, this definition has led to a wide range
of optimal 25(OH) vitamin D concentration thresholds
(20 to 115 nmol/L). More recently (40), the optimal
threshold concentration of 25(OH) vitamin D, based on
bone mineral density levels, was found to be at least 78
nmol/L, with a target of 92 to 105 nmol/L. Randomized
trials of vitamin D supplementation (with or without cal-
cium) that brought mean serum 25(OH) vitamin D con-
centrations up to 75 to 102.5 nmol/L found significantly
lower fracture rates (41). Trials in which the mean serum
25(OH) vitamin D concentration did not reach this
threshold showed no overall effect on fractures (42, 43).
However, in the largest study to date (43), a 29% (CI, 3%
to 48%) reduction in the hazard of hip fracture was ob-
served among adherent women, even though they did not
achieve this threshold 25(OH) vitamin D concentration.
The WHI Calcium–Vitamin D Trial (43) found no
relationship between serum 25(OH) vitamin D concentra-
tion and fracture. However, the characteristics of women
in that trial differed from those of the women in our study.
More than 50% of the women in the WHI Calcium–
Vitamin D Trial were receiving hormone therapy, whereas
we excluded women receiving any bone-active agents from
our analysis. In addition, the WHI trial used different cut-
points, and the results of the trial analyses were unadjusted.
Our study has several limitations. Although we
matched each case-patient to a control participant whose
blood draw date was within 120 days of that of the case-
patient, seasonal variability in 25(OH) vitamin D concen-
trations could have confounded our results. Nonwhite
women are more likely to be vitamin D–deficient (44);
however, only 20 hip fractures occurred in nonwhite
women. We could not test whether the association be-
tween low 25(OH) vitamin D concentration and hip frac-
ture was mediated by bone mineral density because only 3
WHI clinics measured bone mineral density; however, the
NHANES III (7) found this association to be independent
of bone density. We measured total 25(OH) vitamin D
concentrations and did not distinguish 25(OH) vitamin
D2 from 25(OH) vitamin D3. However, reporting vitamin
D2 and vitamin D3 concentrations separately has been
shown to cause some clinical confusion (45). We did not
measure parathyroid hormone, which could contribute to
the relationship between 25(OH) vitamin D concentra-
tions and hip fracture. The study included few women
with 25(OH) vitamin D concentrations greater than 75
nmol/L, so we could not test whether even higher concen-
trations offer greater protection against hip fracture risk.
Finally, we used an observational study design and adjusted
for many factors that could confound the association; how-
ever, unmeasured factors may have caused residual con-
founding.
Despite these limitations, we conclude that low serum
25(OH) vitamin D concentrations are associated with an
increased risk for hip fracture in community-dwelling
women. The mechanism of association is unclear; however,
our findings suggest that low serum 25(OH) vitamin D
concentrations might help identify women at high risk for
hip fracture.
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